ClinicalTrials.gov
public full text
Public Domain
CART-EGFRvIII + Pembrolizumab in GBM
This is an open-label, phase 1 study to assess the safety and tolerability of EGFRvIII T cells in combination with pembrolizumab (PD-1 Inhibitor) in patients with newly diagnosed, EGFRvIII+, MGMT-unmethylated glioblastoma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM#1059453
- Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme#842287
- D2C7-IT With Atezolizumab for Recurrent Gliomas#848505
- A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)#1087935
- Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma#850314
Record · ID 1246154
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive